FINWIRES · TerminalLIVE
FINWIRES

Entrada Therapeutics Shares Decline After Duchenne Muscular Dystrophy Drug Reportedly Misses Analyst Expectations

By

Entrada Therapeutics (TRDA) shares were down nearly 58% in Thursday afternoon trading after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.

Entrada said Thursday that treated patients showed a 2.36% increase in dystrophin over a baseline of 4%.

William Blair analyst Myles Minter expected a placebo-adjusted dystrophin increase of at least 10% as his base case for the drug, while the firm's own model estimated around 11%, Reuters reported.

The data also compares unfavorably with del-zota, Avidity Biosciences' rival exon-44 skipping drug, which reported placebo-adjusted dystrophin increases of around 25% in its early-to-mid stage trial. Oppenheimer analysts had set that benchmark for Entrada's success as well, Reuters said.

Price: $6.77, Change: $-9.26, Percent Change: -57.77%

Related Articles

Wire

Fastly Swings to Q1 Adjusted Earnings as Revenue Rises; Shares Tumble After Hours

Fastly (FSLY) reported Q1 adjusted earnings late Wednesday of $0.13 per diluted share, compared with the loss of $0.05 a year earlier.Analysts polled by FactSet expected earnings of $0.08.Revenue in the three months ended March 31 rose to $173 million from $144.5 million a year earlier.Analysts surveyed by FactSet expected $171.8 million.Fastly expects Q2 non-GAAP net income of $0.05 to $0.08 a share on revenue of $170 million to $176 million. Analysts polled by FactSet project EPS of $0.04 on revenue of $169.8 million.The company expects full-year non-GAAP net income of $0.27 to $0.33 a share on revenue of $710 million to $725 million. Analysts project EPS of $0.27 on revenue of $712 million.Fastly shares tumbled 28% in after-hours trading.

$FSLY
Wire

Tutor Perini Q1 Adjusted Earnings, Revenue Rise; Shares Fall After Hours

Tutor Perini (TPC) reported Q1 adjusted earnings late Wednesday of $1.03 per diluted share, up from $0.65 a year earlier.Four analysts polled by FactSet expected $0.95.Revenue in the three months ended March 31 rose to $1.39 billion from $1.25 billion a year earlier.Four analysts surveyed by FactSet expected $1.44 billion.The company affirmed its full-year adjusted EPS guidance of $4.90 to $5.30. Analysts expect $5.Tutor Perini shares fell 6.6% in after-hours trading.

$TPC
Wire

Murphy Oil Q1 Adjusted Earnings Fall, Revenue Rises

Murphy Oil (MUR) reported Q1 adjusted earnings late Wednesday of $0.32 per diluted share, down from $0.56 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended March 31 rose to $733.6 million from $665.2 million a year earlier.Analysts surveyed by FactSet expected $703 million.Murphy shares fell 2.3% in after-hours trading.

$MUR